Idiopathic Pulmonary Fibrosis Market

1. Idiopathic Pulmonary Fibrosis (IPF) DelveInsight’s ‘Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of IPFs in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Idiopathic Pulmonary Fibrosis (IPF) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market. Idiopathic Pulmonary Fibrosis (IPF) - Disease Understanding and Treatment Algorithm Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia which is found to affect the middle-aged and older adults; and affects lung tissue (alveoli in particular) by either thickening, stiffening, or persistent and progressive scarring (fibrosis) which increases irreversibly over time. If an individual has IPF, scarring affects the air sacs, limiting the amount of oxygen that gets into the blood. With less oxygen in the blood, one can get breathlessness from everyday activities, like walking. This group of lung disorders is also known as ‘Diffuse Parenchymal Lung Diseases,’ which is characterized by a broader umbrella of ‘Interstitial Lung Diseases (IDLs). The DelveInsight Idiopathic Pulmonary Fibrosis (IPF) market report gives the thorough understanding of the Idiopathic Pulmonary Fibrosis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Idiopathic Pulmonary Fibrosis in the US, Europe and Japan. Idiopathic Pulmonary Fibrosis Epidemiology The Idiopathic Pulmonary Fibrosis (IPF) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Prevalent cases of by severity and Gender-specific cases of IPF) scenario of Idiopathic Pulmonary Fibrosis (IPF) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2030. According to DelveInsight, the total number of prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in 7 MM was found to be 229,170, in the year 2017. Idiopathic Pulmonary Fibrosis Drug Chapters IPF, Age-specific cases, Prevalence

2. This segment of the Idiopathic Pulmonary Fibrosis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. Currently, there are two approved drugs in the market; Esbriet (Pirfenidone) and Ofev (Nintedanib) aims at slowing down the disease progression through acting like anti-fibrotic mediators. Nintedanib is a potent intracellular inhibitor of the receptor tyrosine kinases PDGFR, FGFR, vascular endothelial growth factor receptor (VEGFR) and non-receptor tyrosine kinases of the Src family; Pirfenidone, on the other, is responsible for reducing markers of oxidative stress, reducing the proliferation of lung fibroblasts and their differentiation into myofibroblasts by attenuating key TGF-β-induced signalling pathways (i.e., Smad3, p38, and Akt), reducing the expression of TGF-β-induced heat-shock protein 47 (HSP47), which is involved in processing/secretion of procollagen, and reducing expression of α smooth muscle actin (α-SMA) and collagen type 1. Idiopathic Pulmonary Fibrosis Market Outlook The Idiopathic Pulmonary Fibrosis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. According to DelveInsight, the market of Idiopathic Pulmonary Fibrosis in 7MM was found to be USD 1,510.4 Million in 2017, and is expected to increase during the course of the study period (2017–2030). Among the 7MM, the United States accounts for the largest market size of IPF, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. Idiopathic Pulmonary Fibrosis Drugs Uptake This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017–2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. Request for full report @https://www.delveinsight.com/sample- request/idiopathic-pulmonary-fibrosis-market Frequently asked questions: What is Idiopathic Pulmonary Fibrosis? Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive disease characterized by the aberrant accumulation of fibrotic tissue in the lungs parenchyma, associated with significant morbidity and poor prognosis. What was the Idiopathic Pulmonary Fibrosis market size in the 7 major markets (7MM)?

3. Idiopathic Pulmonary Fibrosis Market Size was 1,510 Million in the 7MM in 2017 Which geography accounted for the largest Idiopathic Pulmonary Fibrosis market size? The US accounted for the largest Idiopathic Pulmonary Fibrosis market size among the 7MM What are the Idiopathic Pulmonary Fibrosis market drivers? The grant of special regulatory designations, several therapies in the pipeline from various companies, an increase in the prevalence of fibrotic diseases are the Idiopathic Pulmonary Fibrosis market drivers What are the Idiopathic Pulmonary Fibrosis market barriers? The prognosis of patients with Idiopathic Pulmonary Fibrosis remains poor, lack of accurate diagnostic procedures and, specific validating biomarkers, Idiopathic Pulmonary Fibrosis is associated with high mortality rates are the Idiopathic Pulmonary Fibrosis market barriers How many companies are developing drugs for Idiopathic Pulmonary Fibrosis? MediciNova, FibroGen, Kadmon Corporation, Promedior, Inc, Galapagos NV are developing drugs for Idiopathic Pulmonary Fibrosis For more related reports, visit: https://www.delveinsight.com/report-store.php